ATE510543T1 - Verwendung cilobradines oder seiner pharmazeutisch annehmbaren salze für die behandlung oder prävention von herzinsuffizienz - Google Patents

Verwendung cilobradines oder seiner pharmazeutisch annehmbaren salze für die behandlung oder prävention von herzinsuffizienz

Info

Publication number
ATE510543T1
ATE510543T1 AT03771064T AT03771064T ATE510543T1 AT E510543 T1 ATE510543 T1 AT E510543T1 AT 03771064 T AT03771064 T AT 03771064T AT 03771064 T AT03771064 T AT 03771064T AT E510543 T1 ATE510543 T1 AT E510543T1
Authority
AT
Austria
Prior art keywords
cilobradines
prevention
treatment
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
AT03771064T
Other languages
English (en)
Inventor
Brian Guth
Juergen Daemmgen
Randolph Seidler
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE510543(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of ATE510543T1 publication Critical patent/ATE510543T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03771064T 2002-07-25 2003-07-21 Verwendung cilobradines oder seiner pharmazeutisch annehmbaren salze für die behandlung oder prävention von herzinsuffizienz ATE510543T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (de) 2002-07-25 2002-07-25 Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
PCT/EP2003/007929 WO2004011006A1 (en) 2002-07-25 2003-07-21 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (1)

Publication Number Publication Date
ATE510543T1 true ATE510543T1 (de) 2011-06-15

Family

ID=29265956

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02016602T ATE257384T1 (de) 2002-07-25 2002-07-25 Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
AT03771064T ATE510543T1 (de) 2002-07-25 2003-07-21 Verwendung cilobradines oder seiner pharmazeutisch annehmbaren salze für die behandlung oder prävention von herzinsuffizienz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02016602T ATE257384T1 (de) 2002-07-25 2002-07-25 Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen

Country Status (29)

Country Link
US (1) US20130317008A1 (de)
EP (2) EP1362590B1 (de)
JP (3) JP2005533853A (de)
KR (1) KR20050074432A (de)
CN (1) CN100502874C (de)
AR (1) AR040690A1 (de)
AT (2) ATE257384T1 (de)
AU (1) AU2003254554B8 (de)
BR (1) BR0312852A (de)
CA (1) CA2493208C (de)
CO (1) CO5700723A2 (de)
CY (1) CY1112173T1 (de)
DE (1) DE60200160T2 (de)
DK (2) DK1362590T3 (de)
ES (2) ES2211846T3 (de)
HR (1) HRP20050075B1 (de)
MX (1) MXPA05000617A (de)
MY (1) MY128529A (de)
NZ (1) NZ538424A (de)
PE (1) PE20040706A1 (de)
PL (1) PL214716B1 (de)
PT (2) PT1362590E (de)
SA (1) SA03240350B1 (de)
SI (2) SI1362590T1 (de)
TR (1) TR200400127T4 (de)
TW (1) TWI319321B (de)
UY (1) UY27910A1 (de)
WO (1) WO2004011006A1 (de)
ZA (1) ZA200500084B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362590B1 (de) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
JPWO2007023775A1 (ja) * 2005-08-23 2009-02-26 アステラス製薬株式会社 心房細動治療剤
EP1762179A1 (de) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Methode zur Verbesserung der Qualität der Diagnostik in der Echokardiographie
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
WO2013024036A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim Vetmedica Gmbh Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
DE60009287T2 (de) * 1999-06-03 2005-02-17 Yamanouchi Pharmaceutical Co., Ltd. Neuartige isoquinolin-derivate oder salze davon
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1362590B1 (de) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen

Also Published As

Publication number Publication date
CN1671392A (zh) 2005-09-21
EP1534296A1 (de) 2005-06-01
ES2211846T3 (es) 2004-07-16
DK1534296T3 (da) 2011-08-15
CO5700723A2 (es) 2006-11-30
NZ538424A (en) 2006-10-27
WO2004011006A1 (en) 2004-02-05
AU2003254554A1 (en) 2004-02-16
JP2005533853A (ja) 2005-11-10
BR0312852A (pt) 2005-04-19
CA2493208C (en) 2011-11-01
SA03240350B1 (ar) 2007-10-29
UY27910A1 (es) 2004-02-27
CN100502874C (zh) 2009-06-24
TR200400127T4 (tr) 2004-02-23
TWI319321B (en) 2010-01-11
DE60200160T2 (de) 2004-11-04
HRP20050075B1 (hr) 2013-12-20
EP1362590A1 (de) 2003-11-19
KR20050074432A (ko) 2005-07-18
AU2003254554B8 (en) 2009-02-26
TW200412974A (en) 2004-08-01
SI1534296T1 (sl) 2011-09-30
SI1362590T1 (sl) 2004-04-30
MXPA05000617A (es) 2005-08-19
US20130317008A1 (en) 2013-11-28
JP2009256379A (ja) 2009-11-05
PT1362590E (pt) 2004-05-31
HRP20050075A2 (en) 2005-12-31
EP1362590B1 (de) 2004-01-07
ZA200500084B (en) 2005-10-26
AR040690A1 (es) 2005-04-13
PE20040706A1 (es) 2004-12-06
ES2367109T3 (es) 2011-10-28
PL372993A1 (en) 2005-08-08
DE60200160D1 (de) 2004-02-12
CA2493208A1 (en) 2004-02-05
JP2013166781A (ja) 2013-08-29
DK1362590T3 (da) 2004-03-29
CY1112173T1 (el) 2015-12-09
AU2003254554B2 (en) 2009-01-29
EP1534296B1 (de) 2011-05-25
EP1362590A8 (de) 2004-02-25
PL214716B1 (pl) 2013-09-30
MY128529A (en) 2007-02-28
ATE257384T1 (de) 2004-01-15
PT1534296E (pt) 2011-08-18

Similar Documents

Publication Publication Date Title
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
NO20034590D0 (no) Fremgangsmåter for behandling av vaskul¶r sykdom
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
HUS1300073I1 (hu) Fluorszubsztituált omega-karboxiaril-difenil-karbamid betegségek és egyéb állapot kezelésére és megelõzésére
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE60313125D1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
EP1485109A4 (de) Gefässtherapeutika
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
ATE510543T1 (de) Verwendung cilobradines oder seiner pharmazeutisch annehmbaren salze für die behandlung oder prävention von herzinsuffizienz
DE602004016491D1 (de) Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE369136T1 (de) Therapeutische behandlung
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
ATE526958T1 (de) Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
ATE516040T1 (de) Zusammensetzung und verwendung zur vorbeugung oder behandlung von stomatitis
ATE476974T1 (de) Verwendung einer kombination von l-carnitin, acetyl l-carnitin und propionyl l-carnitin zur behandlung von oligoasthenoteratospermia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534296

Country of ref document: EP